Recommended

Novo Nordisk bids $6.5bn for Metsera Therapeutics
MHRA to streamline UK rare disease drug regulatory pathway
Lilly invests €2.6bn in Netherlands manufacturing facility
MHRA recruits first Chief Medical and Scientific Officer
Galapagos to exit cell therapy business
Chiesi expands French metered dose inhaler facility
CPHI Milan to add AI zone for 2026
Hovione invests $100m in US spray drying manufacturing
news

Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics

1
SHARES

The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia.

Ipsen ImCheck Therapeutics

Credit: HJBC / Shutterstock.com

Ipsen is set to acquire French biotech ImCheck Therapeutics in a move that will strengthen its oncology pipeline by adding rights to a potential first-in-class anti-BTN3A monoclonal antibody.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

ImCheck’s lead asset ICT01 is currently being evaluated in an ongoing phase I/II EVICTION trial in first line acute myeloid leukaemia (AML) patients who are ineligible for intensive chemotherapy.

The biologic’s unique mechanism of action modulates both innate and adaptive immunity and recent clinical data suggests that in combination with Ven-Aza (venetoclax and azacitidine) ICT01 has potential as a novel immunotherapy for AML. 

recent clinical data suggests that in combination with Ven-Aza (venetoclax and azacitidine) ICT01 has potential as a novel immunotherapy for AML”

David Loew, Ipsen’s CEO, said: “We feel confident that with the ICT01 promising data combined with Ipsen’s global development and commercialisation expertise, we are well positioned to start a phase IIb/III trial in 2026.” 

Interim data from the EVICTION trial, presented at the American Society of Clinical Oncology (ASCO) 2025 congress, showed that the combination therapy nearly doubled treatment response relative to historical standard of care data across all molecular subtypes in newly diagnosed patients.

The findings suggest that ICT01-mediated γ9δ2 T cell activation could be the first immunotherapeutic option for newly diagnosed AML patients ineligible for induction chemotherapy.

The deal is expected to close by the end of the first quarter of 2026 and will involve an initial €350 million to ImCheck Therapeutics shareholders, with total payments set to reach €1 billion if all milestones are met.

For Ipsen it adds to its July 2024 oncology licensing deal with Day One Biopharmaceuticals for rights to the kinase inhibitor tovorafenib in a paediatric indication. At the time of that announcement, like ICT01, tovorafenib was being investigated as a potential combination treatment.

Takeda also made a move this week to strengthen its oncology pipeline. Through a new partnership agreement with Innovent Biologics valued initially at $1.2 billion, Takeda could add a potential first-in-class antibody drug to its pipeline.

Share via
Share via